ArticleCellular and molecular life sciences : CMLS2009
Celiac disease IgA modulates vascular permeability in vitro through the activity of transglutaminase 2 and RhoA.
Article in Cellular and molecular life sciences : CMLS, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 55 citations in OpenAlex.
- Intestinal celiac disease - related autoantibodies.Frontiers in immunology · 2025Review
- Cardiomyopathy in Celiac Disease: A Systematic Review.Journal of clinical medicine · 2024Review
- Retinal and choroidal vascular changes in newly diagnosed celiac disease: An optical coherence tomography angiography study.Indian journal of ophthalmology · 2022Article
- Coeliac Disease Pathogenesis: The Uncertainties of a Well-Known Immune Mediated Disorder.Frontiers in immunology · 2020Review
- Transglutaminase 2 and Transglutaminase 2 Autoantibodies in Celiac Disease: a Review.Clinical reviews in allergy & immunology · 2019Review
- Anti-type 2 transglutaminase antibodies as modulators of type 2 transglutaminase functions: a possible pathological role in celiac disease.Cellular and molecular life sciences : CMLS · 2018Review
- Cardiovascular involvement in celiac disease.World journal of cardiology · 2017Review
- Epitope-dependent Functional Effects of Celiac Disease Autoantibodies on Transglutaminase 2.The Journal of biological chemistry · 2016Article
- Elderly Onset Celiac Disease: A Narrative Review.Clinical medicine insights. Gastroenterology · 2016Review
- Activity-regulating structural changes and autoantibody epitopes in transglutaminase 2 assessed by hydrogen/deuterium exchange.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Celiac disease patient IgA antibodies induce endothelial adhesion and cell polarization defects via extracellular transglutaminase 2.Cellular and molecular life sciences : CMLS · 2014Article
- Autoantibodies against MHC class I polypeptide-related sequence A are associated with increased risk of concomitant autoimmune diseases in celiac patients.BMC medicine · 2014Article
- Transglutaminase 2-specific autoantibodies in celiac disease target clustered, N-terminal epitopes not displayed on the surface of cells.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- Nonclassically Secreted Regulators of Angiogenesis.Angiology: open access · 2013Article
- Article
- A celiac cellular phenotype, with altered LPP sub-cellular distribution, is inducible in controls by the toxic gliadin peptide P31-43.PloS one · 2013Article
- Thioredoxin is involved in endothelial cell extracellular transglutaminase 2 activation mediated by celiac disease patient IgA.PloS one · 2013Article
- The adaptive immune response in celiac disease.Seminars in immunopathology · 2012Review
- RhoB is associated with the anti-angiogenic effects of celiac patient transglutaminase 2-targeted autoantibodies.Journal of molecular medicine (Berlin, Germany) · 2012Article
- A single conformational transglutaminase 2 epitope contributed by three domains is critical for celiac antibody binding and effects.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Celiac disease is characterized by the presence of specific autoantibodies targeted against transglutaminase 2 (TG2) in untreated patients' serum and at their production site in the small-bowel mucosa below the basement membrane and around the blood vessels. As these autoantibodies have biological activity in vitro, such as inhibition of angiogenesis, we studied if they might also modulate the endothelial barrier function. Our results show that celiac disease patient autoantibodies increase endothelial permeability for macromolecules, and enhance the binding of lymphocytes to the endothelium and their transendothelial migration when compared to control antibodies in an endothelial cell-based in vitro model. We also demonstrate that these effects are mediated by increased activities of TG2 and RhoA. Since the small bowel mucosal endothelium serves as a "gatekeeper" in inflammatory processes, the disease-specific autoantibodies targeted against TG2 could thus contribute to the pathogenic cascade of celiac disease by increasing blood vessel permeability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.